ASP8374 + Pembrolizumab
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors
Trial Timeline
Sep 8, 2017 → May 10, 2022
NCT ID
NCT03260322About ASP8374 + Pembrolizumab
ASP8374 + Pembrolizumab is a phase 1 stage product being developed by Astellas Pharma for Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03260322. Target conditions include Advanced Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03260322 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Solid Tumors